MA52499A - Associations pour le traitement du cancer - Google Patents

Associations pour le traitement du cancer

Info

Publication number
MA52499A
MA52499A MA052499A MA52499A MA52499A MA 52499 A MA52499 A MA 52499A MA 052499 A MA052499 A MA 052499A MA 52499 A MA52499 A MA 52499A MA 52499 A MA52499 A MA 52499A
Authority
MA
Morocco
Prior art keywords
cancer treatment
treatment associations
associations
cancer
treatment
Prior art date
Application number
MA052499A
Other languages
English (en)
Inventor
Scott Boiko
Justin Cidado
Lisa Drew
Theresa Proia
Martin Maryann San
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA52499A publication Critical patent/MA52499A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA052499A 2018-04-30 2019-04-29 Associations pour le traitement du cancer MA52499A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
MA52499A true MA52499A (fr) 2021-04-14

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052499A MA52499A (fr) 2018-04-30 2019-04-29 Associations pour le traitement du cancer

Country Status (14)

Country Link
US (1) US20210030718A1 (fr)
EP (1) EP3787620A1 (fr)
JP (1) JP2021522246A (fr)
KR (1) KR20210005182A (fr)
CN (1) CN112040944A (fr)
AU (1) AU2019263026B2 (fr)
BR (1) BR112020022020A2 (fr)
CA (1) CA3097486A1 (fr)
EA (1) EA202092540A1 (fr)
MA (1) MA52499A (fr)
MX (1) MX2020011453A (fr)
SG (1) SG11202010528XA (fr)
TW (1) TW202014184A (fr)
WO (1) WO2019211721A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7575454B2 (ja) * 2019-11-04 2024-10-29 アストラゼネカ・アクチエボラーグ Ｂ細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ
US20230192720A1 (en) * 2019-12-18 2023-06-22 Zeno Management, Inc. Macrocyclic compounds
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012285987C1 (en) 2011-07-19 2016-09-08 Merck Sharp & Dohme B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as Btk- inhibitors
AU2015300966A1 (en) * 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
SMT202000249T1 (it) * 2016-04-22 2020-07-08 Astrazeneca Ab Inibitori di mcl1 macrociclici per il trattamento di cancro
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
KR20210005182A (ko) 2021-01-13
EP3787620A1 (fr) 2021-03-10
US20210030718A1 (en) 2021-02-04
CA3097486A1 (fr) 2019-11-07
AU2019263026A1 (en) 2020-12-17
AU2019263026B2 (en) 2022-06-30
EA202092540A1 (ru) 2021-03-17
BR112020022020A2 (pt) 2021-02-02
TW202014184A (zh) 2020-04-16
WO2019211721A1 (fr) 2019-11-07
SG11202010528XA (en) 2020-11-27
CN112040944A (zh) 2020-12-04
JP2021522246A (ja) 2021-08-30
MX2020011453A (es) 2020-12-07

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
MA47408A (fr) Traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
MA52627A (fr) Traitement du cancer
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3733175A4 (fr) Traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3793544A4 (fr) Compositions bifonctionnelles pour le traitement du cancer
EP3787625A4 (fr) Méthodes de traitement du cancer
EP3411073A4 (fr) Combinaisons pour le traitement du cancer
EP3773625A4 (fr) Méthodes et matériels pour le traitement du cancer